Indian Pharma Companies Analyzed: A Strategic Look

Indian pharmaceutical companies are looking stronger than their rivals in the United States. This is because they have a clearer picture of how much money they’ll make and aren’t as affected by rising drug prices in America. Experts at Antique Stock Broking believe India’s drug market will grow by about 10 to 11 percent, largely thanks to new medicines and increased demand.

Key Points

• Stronger India market growth than the US.
• Indian companies face less price pressure.
• GLP-1 therapies boost India’s growth.
• Domestic growth: 12% CAGR (2025-28).
• US firms struggle with falling prices.
• Torrent Pharmaceuticals is a top pick.

What’s Happening in the US?

US-based drug companies are facing problems. Drug prices are going down, and they need to find new drugs to sell to make money. A key drug called Revlimid will become cheaper in 2026, which will hurt their profits. Companies are trying to sell more drugs like generic Advair, Abraxane, and Symbicort.

India’s Growing Market

India’s drug market is growing quickly. Experts predict a 12% increase in growth over the next few years. This growth is driven by new medicines and more people needing them.

Challenges and Changes

However, there are also challenges. The US is changing its trade rules, which could make it harder for Indian drug companies to sell their products there. Also, many drugs will lose their protection from patents soon, meaning more companies can make them, increasing competition.

Brokerage Recommendations

Antique Stock Broking recommends investing in Torrent Pharmaceuticals (buy), Cipla and Dr Reddy’s Laboratories (hold), and Concord Biotech (buy). They see Torrent as the best choice.

Pharmaceutical investment decisions require thorough, expert analysis before implementation.